Biotech Finance
2 articles
Venture Capital
Inside Formation Bio's $600 Million Hub-and-Spoke Drug Development Fund
Formation Bio has launched a $600 million fund using a novel "hub-and-spoke" model to acquire and advance drug programs through clinical development. This structure separates financial risk per asset from a centralized operating platform, aiming to overcome clinical development bottlenecks.
Marco Giuliani·November 5, 2026
Venture Capital
Formation Bio's $600 Million Accelerator Fund: How an AI-Native Pharma Company Is Turning Drug Development Into an Asset Class
Formation Bio has launched a $600 million fund to acquire individual clinical-stage drug assets, housing each in a separate entity while developing them through a unified, AI-driven organization. This novel approach aims to transform drug development into an investable asset class by addressing the post-discovery bottleneck.
Marco Giuliani·November 5, 2026